Patient characteristics at baseline
| Characteristic . | Transient MG . | Persistent MG . | P . |
|---|---|---|---|
| Baseline | |||
| Age | 44.5 (35.5-58) | 43 (20-55.5) | .49 |
| Gender (M/F) | 10/2 | 6/3 | .61 |
| Hemoglobin (g/L) | 14.4 (12.6-15) | 13.7 (12.8-14.3) | .77 |
| Calcium (µM) | 2.5 (2.4-2.5) | 2.48 (2.37-2.55) | .81 |
| Total urine protein (g/L) | 0.15 (0.13-0.31) | 0.14 (0.05-0.54) | .78 |
| Chronic viral hepatitis | 4/12 (3 HCV, 1 HBV) | 4/9 (3 HCV, 1 HBV) | .67 |
| CMV reactivation* | 4/12 | 1/9 | .34 |
| CD4+ count (cells/µL) | 221(87-285) | 145 (72-227) | .65 |
| Plasma HIV RNA (copies/mL)† | 23339 (10,805-319 000) | 29540 (9305-688 000) | .58 |
| Type of MG | 6 IgGκ, 6 IgGλ | 6 IgGκ, 3 IgGλ | .66 |
| After prolonged ART (≥5 y) | |||
| CD4+ count (cells/µL) | 326 (228-554) | 304 (172-558) | .93 |
| Nadir CD4+ count (cells/µL) | 116 (31-195) | 61 (31-93) | .5 |
| Cumulative detectable HIV† | 0.5 (0-1) | 1.5 (0-4) | .04 |
| CD8+ CD38bright (%) | 6.2 (3.7-11.4) | 12.2 (7.9-38.9) | .06 |
| ART regiment | |||
| NRTI+NNRTI | 5/12 | 3/9 | 1 |
| NRTI+PI | 6/12 | 6/9 | .66 |
| Other | 1/12 | 0/9 | 1 |
| Duration of ART | 9 (7-10) | 9 (7-12) | .95 |
| Characteristic . | Transient MG . | Persistent MG . | P . |
|---|---|---|---|
| Baseline | |||
| Age | 44.5 (35.5-58) | 43 (20-55.5) | .49 |
| Gender (M/F) | 10/2 | 6/3 | .61 |
| Hemoglobin (g/L) | 14.4 (12.6-15) | 13.7 (12.8-14.3) | .77 |
| Calcium (µM) | 2.5 (2.4-2.5) | 2.48 (2.37-2.55) | .81 |
| Total urine protein (g/L) | 0.15 (0.13-0.31) | 0.14 (0.05-0.54) | .78 |
| Chronic viral hepatitis | 4/12 (3 HCV, 1 HBV) | 4/9 (3 HCV, 1 HBV) | .67 |
| CMV reactivation* | 4/12 | 1/9 | .34 |
| CD4+ count (cells/µL) | 221(87-285) | 145 (72-227) | .65 |
| Plasma HIV RNA (copies/mL)† | 23339 (10,805-319 000) | 29540 (9305-688 000) | .58 |
| Type of MG | 6 IgGκ, 6 IgGλ | 6 IgGκ, 3 IgGλ | .66 |
| After prolonged ART (≥5 y) | |||
| CD4+ count (cells/µL) | 326 (228-554) | 304 (172-558) | .93 |
| Nadir CD4+ count (cells/µL) | 116 (31-195) | 61 (31-93) | .5 |
| Cumulative detectable HIV† | 0.5 (0-1) | 1.5 (0-4) | .04 |
| CD8+ CD38bright (%) | 6.2 (3.7-11.4) | 12.2 (7.9-38.9) | .06 |
| ART regiment | |||
| NRTI+NNRTI | 5/12 | 3/9 | 1 |
| NRTI+PI | 6/12 | 6/9 | .66 |
| Other | 1/12 | 0/9 | 1 |
| Duration of ART | 9 (7-10) | 9 (7-12) | .95 |
Baseline is defined as the time of detection of M protein before ART initiation and after a long-term period on ART ranging from 5 to 12 years.
Values are median (IQR) unless otherwise indicated. Boldface P values indicate their significance.
HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, interquartile range.
CMV reactivation detected by pp65 antigenemia.
Median years (IQR) with detectable viremia during follow-up.